Clinical Trials Regulation

The way clinical trials are conducted in the European Union (EU) will undergo a major change when the Clinical Trials Regulation (Regulation (EU) No 536/2014) comes into application on 31 January 2022. The Regulation harmonises the assessment and supervision processes for clinical trials throughout the EU, via a Clinical Trials Information System (CTIS). CTIS will contain the centralised EU portal and database for clinical trials foreseen by the Regulation. The European Medicines Agency (EMA) sets up and maintains CTIS, in collaboration with the Member States and the European Commission.

The European Commission confirmed 31 January 2022 as the date of entry into application of the Clinical Trials Regulation and the go-live of CTIS, by publishing a notice in the Official Journal of the European Union on 31 July 2021. 

When the Regulation becomes applicable on 31 January 2022, it will repeal the existing EU Clinical Trials Directive (EC) No. 2001/20/EC and national legislation that was put in place to implement the Directive. It will also apply to trials authorised under the previous legislation if they are still ongoing three years after the Regulation has come into operation.

EMA's Management Board confirmed on 21 April 2021 that CTIS is fully functional and meets the functional specifications following an independent, successful audit. The timing of the Regulation's application required confirmation of full functionality of CTIS through an independent audit.

The authorisation and oversight of clinical trials remains the responsibility of Member States, with EMA managing CTIS and supervising content publication on the public website.

Aims and key benefits of the Regulation

The goal of the Clinical Trials Regulation is to create an environment that is favourable to conducting clinical trials in the EU, with the highest standards of safety for participants and increased transparency of trial information. The Regulation will require:

  • consistent rules for conducting clinical trials throughout the EU;
  • information on the authorisation, conduct and results of each clinical trial carried out in the EU to be publicly available.

This will increase the efficiency of all trials in Europe with the greatest benefit for those conducted in multiple Member States. It aims to foster innovation and research, while helping avoid unnecessary duplication of clinical trials or repetition of unsuccessful trials.

The key benefits of the Regulation include:

  • harmonised electronic submission and assessment process for clinical trials conducted in multiple Member States;
  • improved collaboration, information-sharing and decision-making between and within Member States;
  • increased transparency of information on clinical trials;
  • highest standards of safety for all participants in EU clinical trials.

How the Clinical Trials Information System will work

CTIS will be the single entry point for submitting clinical trial information in the EU, which will be stored in the system. EMA will make information stored in CTIS publicly available subject to transparency rules.

The clinical trial application form and supporting dossier will cover all regulatory and ethics assessments from the Member States concerned. It will also include the public registration of the clinical trial and any subsequent updates.

EMA published the functional specifications for the EU portal and database available through CTIS to be audited in December 2014, following a public consultation:

The system will support the day-to-day business processes of Member States and sponsors throughout the life-cycle of a clinical trial in a user-friendly way.

It will provide regulatory oversight of clinical trials and tools for supervision and monitoring.

It will contain collaboration tools, workflow and document management capabilities, accessible via individual workspaces.

Sponsor workspace

A secure workspace will assist clinical trial sponsors in preparing and compiling data to submit to the system for assessment by Member States. It will allow sponsors to:

  • manage users and user roles within their organisations;
  • compile clinical trial application dossiers for new and updated trials;
  • cross-reference to product documents in other clinical trials;
  • upload documents for clinical trial application submission;
  • receive alerts and notifications for ongoing trials;
  • respond to requests for information and view deadlines;
  • search and access clinical trials;
  • record clinical trial results.

Authority workspace

A secure workspace will support the activities of Member States and the European Commission in overseeing clinical trials. It will allow Member States to:

  • manage users and user roles within their organisations;
  • view clinical trial application dossiers;
  • manage tasks related to the assessment of clinical trials;
  • collaborate within and between Member States;
  • receive alerts and notifications for ongoing trials;
  • download documents submitted by clinical trial sponsors;
  • record inspections of sites and clinical trials.

Public website

Through the website, members of the public can access detailed information on all clinical trials conducted in the EU, in all official EU languages. The website will provide the following features:

  • overview of clinical trial statistics;
  • advanced search;
  • download data and reports;
  • site updates and announcements.

Clinical Trials Information System development

CTIS is due to go live on 31 January 2022.

EMA's Management Board endorsed a delivery timeframe in December 2015. However, the system's go-live date was postponed due to technical difficulties with the development of the IT system.

The IT supplier submitted to EMA a revised project plan with improved project management, development and testing processes, resources and increased contingency. EMA also subsequently revised the CTIS project methodology and delivery plan.

Since June 2019, the development of CTIS followed an agile and iterative delivery model, with functionalities delivered in short development cycles. This is based on a revised project plan from the IT supplier, with improved project management, development and testing processes, resources and increased contingency.

Member States and stakeholders are directly engaged in the development of CTIS through nominated ‘product owners’ to ensure their expectations are taken into account. This means that nominated business experts representing user groups from the national competent authorities and ethics committees and from sponsors have an enhanced and continuous opportunity to test, review, select and verify functionalities.

In 2021 EMA is focusing on:

  • the findings of a system audit;
  • improving usability, quality and stability of the CTIS;
  • knowledge transfer to prepare users and their organisations for CTIS.

Update: EMA is working towards go-live, with the plan below.

    Training and supporting materials on how to use CTIS are available to help clinical trial sponsors, national competent authorities, ethics committees, European Commission and EMA staff prepare for using CTIS and comply with their obligations under the Clinical Trials Regulation (Regulation (EU) No 536/2014):

    EMA is providing regular progress updates on the development of CTIS to its Management Board. For further details, see the highlights published after the meetings of the Management Board.

    EMA and the Member States are fully committed to ensuring the success of this project and its delivery. This remained a priority during EMA's preparation for Brexit and its relocation to Amsterdam

    For more information on the original delivery timeframe, see:

    Progress updates

    Progress updates are available below on the development of CTIS and its functionalities, and rollout of training and user support.

    These include the CTIS Highlights newsletter, published quarterly in 2021. Newsletter editions start from June 2020. 

    To subscribe to the newsletter, write to

    Transparency rules

    The Clinical Trials Regulation requires all information stored in the database to be publicly available, unless exempted under the Regulation to protect:

    • personal data;
    • commercially confidential information, in particular the marketing-authorisation status of the medicine, unless there is an overriding public interest;
    • confidential communication between Member States in the preparation of their assessment;
    • supervision of clinical trials by Member States.

    EMA has added two sets of requirements to the functional specifications for applying the exceptions:

    • features to support making information public;
    • disclosure rules describing the practical implementation of the transparency rules.

    The EMA Management Board endorsed both documents in 2015:

    Public consultations

    European Commission consultations

    In preparation for the implementation of the Regulation, the European Commission published on 1 June 2016 the following guidance documents for public consultation until 31 August 2016: 

    For more information, see European Commission: Clinical trials - Major developments.

    EMA consultations

    The Agency consults on its proposals with EU Member States, the European Commission and stakeholders representing non-commercial and commercial clinical-trial sponsors, healthcare professionals and patient groups.

    EMA consulted on the draft functional specifications in October 2014. A total of 47 individuals and organisations submitted more than 500 comments:

    EMA held a three-month consultation in 2015 on implementing the transparency rules. Over 80 different individuals and organisations submitted more than 1,100 comments:


    How useful was this page?

    Add your rating
    39 ratings
    29 ratings
    15 ratings
    12 ratings
    24 ratings